Characterising aggressive multiple sclerosis
- PMID: 23744892
- DOI: 10.1136/jnnp-2013-304951
Characterising aggressive multiple sclerosis
Abstract
Objective: To explore the occurrence and characteristics of aggressive multiple sclerosis (AMS) in adult-onset multiple sclerosis (MS) patients.
Methods: Prospectively collected data (1980-2009) from British Columbia, Canada, were retrospectively analysed. AMS was defined in three different ways (AMS1, 2 and 3): 'AMS1'--confirmed Expanded Disability Status Scale (EDSS) ≥ 6 within 5 years of MS onset; 'AMS2'--confirmed EDSS ≥ 6 by age 40; and 'AMS3'--secondary progressive MS within 3 years of a relapsing-onset course. Three respective 'non-aggressive' MS comparison cohorts were selected. Patients' characteristics were compared between aggressive and non-aggressive cohorts using multivariable logistic regression, with findings expressed as adjusted OR (AOR) and 95% CI.
Results: Application of the three definitions to the source population of 5891 patients resulted in 235/4285 (5.5%) patients fulfilling criteria for AMS1 (59.6% were female; 74.5% had relapsing-onset MS), 388/2762 (14.0%) for AMS2 (65.2% were female; 92.8% had relapsing-onset MS) and 195/4918 (4.0%) patients for AMS3 (61.0% were female). Compared to the respective control cohorts, those with AMS were more likely to be male (AOR=1.5, 95% CI 1.1 to 2.0 (AMS1); 1.6, 95% CI 1.3 to 2.1 (AMS2); 1.8, 95% CI 1.3 to 2.4 (AMS3)), older at MS symptom onset (AOR=1.1; 95% CI 1.1 to 1.1 (AMS1 and AMS3)) and have primary progressive MS (AOR=2.3, 95% CI 1.6 to 3.3 (AMS1); 2.7, 95% CI 1.7 to 4.4 (AMS2)).
Conclusions: AMS was identified in 4-14% of patients, depending on the definition used. Although there was a relative preponderance of men and primary progressive MS presenting with AMS, the majority of patients were still women and those with relapsing-onset MS.
Keywords: CLINICAL NEUROLOGY; EPIDEMIOLOGY; MULTIPLE SCLEROSIS; NEUROEPIDEMIOLOGY.
Similar articles
-
Disability progression in aggressive multiple sclerosis.Mult Scler. 2017 Mar;23(3):456-463. doi: 10.1177/1352458516653273. Epub 2016 Jul 11. Mult Scler. 2017. PMID: 27325603
-
Natural history of secondary-progressive multiple sclerosis.Mult Scler. 2008 Apr;14(3):314-24. doi: 10.1177/1352458507084264. Epub 2008 Jan 21. Mult Scler. 2008. PMID: 18208898
-
Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.Radiology. 2000 Mar;214(3):665-70. doi: 10.1148/radiology.214.3.r00mr30665. Radiology. 2000. PMID: 10715027
-
Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis.J Neurol Sci. 2003 Feb 15;206(2):135-7. doi: 10.1016/s0022-510x(02)00426-4. J Neurol Sci. 2003. PMID: 12559500 Review.
-
Progressive Forms of Multiple Sclerosis: Distinct Entity or Age-Dependent Phenomena.Neurol Clin. 2018 Feb;36(1):163-171. doi: 10.1016/j.ncl.2017.08.006. Neurol Clin. 2018. PMID: 29157397 Review.
Cited by
-
A study of patients with aggressive multiple sclerosis at disease onset.Neuropsychiatr Dis Treat. 2016 Aug 1;12:1907-12. doi: 10.2147/NDT.S111885. eCollection 2016. Neuropsychiatr Dis Treat. 2016. PMID: 27536112 Free PMC article.
-
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?Nat Rev Neurol. 2014 Jul;10(7):368-70. doi: 10.1038/nrneurol.2014.98. Epub 2014 Jun 3. Nat Rev Neurol. 2014. PMID: 24890645 No abstract available.
-
Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD.Front Neurol. 2022 Nov 7;13:1011579. doi: 10.3389/fneur.2022.1011579. eCollection 2022. Front Neurol. 2022. PMID: 36419536 Free PMC article. Review.
-
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE).Bone Marrow Transplant. 2020 Feb;55(2):283-306. doi: 10.1038/s41409-019-0684-0. Epub 2019 Sep 26. Bone Marrow Transplant. 2020. PMID: 31558790 Free PMC article.
-
Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.Adv Ther. 2020 Feb;37(2):800-818. doi: 10.1007/s12325-019-01186-z. Epub 2019 Dec 23. Adv Ther. 2020. PMID: 31873868 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous